Investors & Media Home

Download Mesoblast Corporate Backgrounder

Mesoblast Corporate Backgrounder (350 KB)

Mesoblast is a world leader in developing innovative cellular medicines.

The Company has established what it believes is the industry's most clinically advanced and diverse portfolio of cell-based product candidates ... More

Latest ASX AnnouncementsMore
13 November 2018
LVAD Results Webcast Presentation
12 November 2018
LVAD Trial Results Provide Potential Regulatory Pathway
12 November 2018
Pause in Trading
09 November 2018
MSB To Host Webcast For Heart Failure Results At AHA
Upcoming EventsMore
There are currently no events scheduled.
Prior to
13 November 2018
Phase 2b Results in End-stage Heart Failure Patients with LVADs
Stock QuoteMore
Exchange :ASX
Price :A$1.47
Change : Stock is Down 0.11 (6.37%)
Volume :5,308,108
Data as of 13 November 2018 4:11 p.m. ET
Data provided by Nasdaq Minimum 15 minutes delay
Download Documentation 2018 Annual Report
Download Documentation Financial Results for the 2018 Full Financial Year, 4th Quarter Ended June 30, 2018
Download Documentation Financial Results for the Period Ended September 30, 2017
Download Documentation Financial Results for the Three Months and for the Year Ended June 30, 2017
E-mail Alerts
Sign up to receive e-mail alerts.

Share Price ASX: MSB  AUD 1.47 as of Nov 13, 2018